Organisation paid for research Program year 2025 Source: CMS Open Payments

Abington Neurological Associates Ltd

Neither a doctor nor a teaching hospital

Research payments

$2,596,061

193 payments

Through program year 2025, Abington Neurological Associates Ltd is reported as receiving $2,596,061 in research payments, across 193 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$83,834	17
2024	Research	$344,979	52
2023	Research	$583,785	50
2022	Research	$603,809	22
2021	Research	$512,029	12
2020	Research	$208,175	13
2019	Research	$259,451	27

Breakdown

Who paid Research payments · program years 2019–2025

Eli Lilly and Company $1,961,327 42 payments
F. Hoffmann-La Roche AG $212,298 43 payments
Harmony Biosciences LLC $99,093 24 payments
Genentech, Inc. $73,426 9 payments
Sage Therapeutics, Inc. $62,524 2 payments
Avadel CNS Pharmaceuticals, LLC $52,124 1 payment
ACADIA Pharmaceuticals Inc $41,579 9 payments
Allergan Inc. $38,466 19 payments
AbbVie, Inc. $18,899 8 payments
GRT US Holding, Inc. $18,025 2 payments

Studies the money was for Research payments · program years 2019–2025

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $748,554 7 payments
Assessment of Safety, Tolerability and Efficacy of Ly3002813 Alone and in Combination With Ly3202626 in Early Symptomatic Alzheimers Disease $434,566 7 payments
A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer's Disease (Trailblazer-Alz 2) $275,351 2 payments
A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-Avwa in Participants With Early Symptomatic Alzheimer's Disease $145,075 4 payments
Roll Over Protocol for 3 Ocr Pivotal Studies Opera I Opera II and Oratorio to Extend the Ole $122,626 31 payments
Donanemab Follow-On Study: Safety, Tolerability, and Efficacy in Symptomatic Alzheimer's Disease With Validation of Remote Neuropsychological Assessments $107,359 6 payments
Second Phase III in RMS $89,672 12 payments
Phase II Study for Moderate Ad $73,426 9 payments
Effect of Ly3154207 on Cognition in Mild to Moderate Parkinsons Disease Dementia PDD - the Presence Study $71,874 4 payments
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Sage-718 in Participants With Mild Cognitive Impairment Or Mild Dementia Due to Alzheimer's Disease $62,524 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.